HIGHLIGHTS
- who: William Damsky from the Yale School of Medicine, New Haven, CT, USAKansas City University of have published the article: Inhibition of type 1 immunity with tofacitinib is associated with marked improvement in longstanding sarcoidosis, in the Journal: NATURE COMMUNICATIONS NATURE COMMUNICATIONS of April/11,/2019
- what: The authors and others have recently described effective treatment of individual patients with sarcoidosis using tofacitinib (JAK1/3 > 2 inhibitor) or ruxolitinib (JAK1/2 inhibitor); however, this approach has not yet been evaluated in a prospective fashion and the key cytokines targeted remain to be fully elucidated19-25 . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.